Trials / Not Yet Recruiting
Not Yet RecruitingNCT06254066
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
An Open-label, Single-arm Study of Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Months – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm, exploratory study planned to include 40 patients with HRD-positive HR +/HER2- advanced breast cancer treated with Adebrelimab in combination with fluzoparib. To observe and evaluate the efficacy and safety of Adebrelimab combined with fluzoparib in the treatment of HRD-positive HR +/HER2-advanced breast cancer
Conditions
- Female Breast Cancer Patients
- Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
- HRD Positive Advanced Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab plus Fluzoparib | Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer |
Timeline
- Start date
- 2024-04-16
- Primary completion
- 2026-09-30
- Completion
- 2028-12-31
- First posted
- 2024-02-12
- Last updated
- 2024-02-12
Source: ClinicalTrials.gov record NCT06254066. Inclusion in this directory is not an endorsement.